Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology

Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology.

Although radionecrosis has been exhaustively described in depth in the neurooncological literature, its diagnosis is still a challenging issue because its radiological pattern is frequently indistinguishable from that of tumor recurrence. This review discusses the causes of radionecrosis and the potential effect of adjuvant chemotherapy concomitant with radiotherapy on its rate and onset. The p...

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.

PURPOSE Standard therapy for glioblastoma (GBM) is temozolomide (TMZ) administration, initially concurrent with radiotherapy (RT), and subsequently as maintenance therapy. The radiologic images obtained in this setting can be difficult to interpret since they may show radiation-induced pseudoprogression (psPD) rather than disease progression. METHODS Patients with histologically confirmed GBM...

Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment.

The role of immunotherapy in treatment of brain metastases is unknown because most trials exclude patients with active brain lesions. As new immunomodulating agents gain approval for many malignancies, it is important to know if they have unique effects in the central nervous system (CNS). Here, we present a case of a patient with progressing brain metastases treated with a single cycle of pemb...

219 Liquid Biopsy Can Distinguish Recurrent Glioblastomas From Pseudoprogression and Radiation Necrosis After Concurrent Radiochemotherapy.

INTRODUCTION Glioblastoma (GBM) is the most lethal primary brain tumor with a median survival of 15 months despite resection and concurrent radiochemotherapy. Among the many challenges in treating glioblastoma patients is the ability to differentiate pseudoprogression (PsP) and "radiation necrosis" (RN) from true recurrent GBM (rGBM). While PsP and RN occur in 15% to 30% of glioblastoma treated...

Title: Melanoma brain metastasis pseudoprogression after pembrolizumab treatment Running head: Brain pseudoprogression after pembrolizumab Authors: